Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy ERYTECH Pharma S-A (ERYP) stocks in Canada

Learn how to easily invest in ERYTECH Pharma S-A stocks.

ERYTECH Pharma S-A is a biotechnology business based in the US. ERYTECH Pharma S-A stocks (ERYP.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.71 – a decrease of 2.62% over the previous week. ERYTECH Pharma S-A employs 196 staff and has a trailing 12-month revenue of around $4.1 million.

How to buy shares in ERYTECH Pharma S-A

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ERYP – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Is it a good time to buy ERYTECH Pharma S-A stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

How has Coronavirus impacted ERYTECH Pharma S-A's stock price?

Since the stock market crash in March caused by coronavirus, ERYTECH Pharma S-A's stock price has had significant negative movement.

Its last market close was $2.23, which is 65.26% down on its pre-crash value of $6.42 and 56.95% down on the lowest point reached during the March crash when the stocks fell as low as $3.5.

If you had bought $1,000 worth of ERYTECH Pharma S-A stocks at the start of February 2020, those stocks would have been worth $672.06 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $327.94.

ERYTECH Pharma S-A stock price (NASDAQ:ERYP)

Use our graph to track the performance of ERYP stocks over time.

ERYTECH Pharma S-A shares at a glance

Information last updated 2022-01-18.
Latest market close$2.23
52-week range$2.09 - $12.00
50-day moving average $2.38
200-day moving average $4.91
Wall St. target price$17.83
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.63

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

ERYTECH Pharma S-A price performance over time

Historical closes compared with the close of $2.23 from 2022-01-18

1 week (2022-01-12) -4.29%
1 month (2021-12-17) 1.36%
3 months (2021-10-19) -62.39%
6 months (2021-07-19) -48.56%
1 year (2021-01-19) -81.43%
2 years (2020-01-17) -68.88%
3 years (2019-01-18) 8
5 years (2017-01-15) N/A

ERYTECH Pharma S-A financials

Revenue TTM $4.1 million
Gross profit TTM $3.7 million
Return on assets TTM -45.13%
Return on equity TTM -151.57%
Profit margin 0%
Book value $1.32
Market capitalisation $73.9 million

TTM: trailing 12 months

ERYTECH Pharma S-A share dividends

We're not expecting ERYTECH Pharma S-A to pay a dividend over the next 12 months.

ERYTECH Pharma S-A share price volatility

Over the last 12 months, ERYTECH Pharma S-A's shares have ranged in value from as little as $2.091 up to $12. A popular way to gauge a stock's volatility is its "beta".

ERYP.US volatility(beta: 1.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ERYTECH Pharma S-A's is 1.6549. This would suggest that ERYTECH Pharma S-A's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

ERYTECH Pharma S-A overview

ERYTECH Pharma S. A. , a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine-dependent cancers. It has research collaborations with the Fox Chase Cancer Center to advance the preclinical development of erymethionase for the treatment of homocystinuria; and Queen's University of Canada to advance the preclinical development of eryminase for the treatment of arginase-1-deficiency. The company was incorporated in 2004 and is headquartered in Lyon, France.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site